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bstract
Tuberculosis (TB) is a leading cause of death amongst infectious diseases. The low permeation of antimycobacterial agents and their difficult
ccess to infected macrophages necessitate long-term use of high drug doses. Liposomes preferentially accumulate in macrophages, increasing
he efficacy of antibiotics against intracellular parasites. In the present work, several rifabutin (RFB) liposomal formulations were developed
nd characterised and their in vivo profile was compared with free RFB following intravenous administration. With the RFB liposomal
ormulations tested, higher concentrations of the antibiotic were achieved in liver, spleen and lungs 24 h post administration compared with
ree RFB. The concentration of RFB in these organs was dependent on the rigidity of liposomal lipids. The liposomal RFB formulation
repared with dipalmitoyl phosphatidylcholine:dipalmitoyl phosphatidylglycerol (DPPC:DPPG) was the most effective and was selected for
iological evaluation in a mouse model of disseminated TB. Compared with mice treated with free RFB, mice treated with the DPPC:DPPG
FB formulation exhibited lower bacterial loads in the spleen (5.53 log vs. 5.18 log ) and liver (5.79 log vs. 5.41 log ). In the lung, the10 10 10 10
evel of pathology was lower in mice treated with encapsulated RFB. These results suggest that liposomal RFB is a promising approach for
he treatment of extrapulmonary TB in human immunodeficiency virus co-infected patients.
2007 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
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b. Introduction
Tuberculosis (TB) is a leading cause of death amongst
nfectious diseases [1]. Furthermore, this re-emerging disease
as become one of the most important infections affect-
ng human immunodeficiency virus (HIV)-positive patients
orldwide [2,3]. Although it is a more severe health prob-em in developing countries, TB has become a renewed
hreat in the Western world since the mid 1980s [4].
n view of this situation, the World Health Organization
∗ Corresponding author. Tel.: +351 21 092 4733; fax: +351 21 716 3636.
E-mail address: Manuela.Gaspar@ineti.pt (M.M. Gaspar).
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oi:10.1016/j.ijantimicag.2007.08.008eclared TB a global public health emergency since 1993
5].
Mycobacterium tuberculosis is a facultative intracellu-
ar parasite that after being phagocytosed by macrophages
s able to survive and multiply within its host cell [6].
evelopment of an adaptive immune response mediated
y T-lymphocytes, with the production of the macrophage-
ctivating cytokine interferon-gamma (IFN) and the
nvolvement of macrophages and lymphocytes in the forma-
ion of granulomata are crucial steps for the control of M.
uberculosis [7,8].
Access of antimycobacterial agents to M. tuberculosis
acilli inside host macrophages is limited due to the low lev-
ls of drug permeation, making it difficult to achieve effective
of Chemotherapy. All rights reserved.
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rug concentrations [9,10]. In addition, degradation of drugs
ay occur before they reach target tissues [11]. Therefore,
onventional treatments for TB include daily therapy with
igh doses of antimycobacterial drugs for at least 6 months.
hese long treatment schedules are associated with severe
ide effects and result in poor compliance, one of the main rea-
ons for the emergence of multidrug-resistant (MDR) strains,
articularly in developing countries. Improvement of antimy-
obacterial therapy is therefore urgently required.
Although the development of new antimycobacterial
rugs is an obvious and necessary strategy to fight TB,
echanisms to improve the efficacy of existing drugs could
epresent a faster approach. In this regard, improvement of the
herapeutic index of existing antimycobacterial drugs should
e considered, aimed at maximisation of its concentration
t infected sites, reduction of toxic effects and reduction
f treatment duration. Liposomes are one of the most
horoughly studied carrier systems and have been succes-
ively used for improving the efficacy of antibiotics directed
gainst intramacrophage infectious agents whilst minimis-
ng adverse side effects [12,13], including for the pathogenic
ycobacteria Mycobacterium avium and M. tuberculosis
14–18].
The rationale behind the use of liposomes as antibiotic
arrier systems in infections by intracellular parasites such
s mycobacteria is based on their inherent tendency to be
aken up by macrophages following systemic administration
19,20]. The physicochemical properties of liposomes play
n important role in their in vivo fate. Thus, it is important
o use a liposomal formulation that, following intravenous
i.v.) administration, does not destabilise, with concomitant
elease of their contents, before reaching their targets. Fur-
hermore, drugs should only become bioavailable when the
iposomes reach the target site and at a rate that would main-
ain the local levels of free drug at a therapeutic concentration
21].
Rifabutin (RFB), a rifamycin spiropiperidyl derivative, is
potent inhibitor of bacterial DNA-dependent RNA poly-
erases [22], with a broad spectrum of antimycobacterial
ctivity [23–25]. RFB is in clinical use for the treatment
f mycobacterial infections caused by M. tuberculosis,
ycobacterium leprae and M. avium, being particularly
mportant in cases of MDR-TB given that development
f resistance to this drug is low [26–31]. In previous
ork using a M. avium model of infection, a superior
herapeutic effect of RFB was demonstrated when incor-
orated in liposomes compared with RFB in the free form
16]. In the present work, it was intended to investigate
he therapeutic effect of liposomal RFB in an experimen-
al disseminated M. tuberculosis infection with regard to
FB antimycobacterial activity as well as its effect on the
rogression of pathology. With this purpose in mind, we
tarted by studying the in vivo fate of various RFB lipo-
omal formulations in order to select the lipid composition
ble to deliver the antibiotic to the highest extent to the
iver, spleen and lung, as these organs are the main targets
o
a
l
tntimicrobial Agents 31 (2008) 37–45
f M. tuberculosis in this experimental model of infec-
ion.
. Materials and methods
.1. Chemical products
RFB was obtained from Pharmacy Biotech AB (Uppsala,
weden). The following pure phospholipids were purchased
rom Lipoid (Ludwigshafen, Germany): egg phosphatidyl-
holine; phosphatidylglycerol; cholesterol (Chol); and
oly(ethylene glycol) (PEG) covalently linked to distearoyl-
hosphatidylethanolamine (DSPE-PEG). Dimyristoyl phos-
hatidylcholine, dimyristoyl phosphatidylglycerol, dipalmi-
oyl phosphatidylcholine (DPPC), dipalmitoyl phosphatidyl-
lycerol (DPPG) and hydrogenated phosphatidylcholine
HPC) were obtained from Avanti Polar Lipids (Alabaster,
L).
.2. Animals
BALB/c mice (6–8 weeks old) were obtained from the
ulbenkian Institute of Science (Oeiras, Portugal) or from
harles River Laboratories (Barcelona, Spain). The animals
ere kept under standard hygiene conditions, fed commercial
how and given acidified drinking water ad libitum. All of the
xperimental procedures were carried out with the permission
f the local laboratory committee.
.3. Preparation of RFB liposomal formulations
Multilamellar vesicles composed of the selected lipids
ere prepared by a remote loading technique with an ammo-
ium sulphate gradient according to Bolotin et al. [32] with
ome modifications. Briefly, the selected phospholipids were
issolved in chloroform and the mixture was dried by rotary
vaporation of the organic solvent to a thin film under a nitro-
en stream. The homogeneous film obtained was dispersed in
buffer solution containing 5% trehalose (w/v) and 60 mM of
mmonium sulphate (pH 5) in a phospholipid concentration
f 32mol/mL. The so-formed empty multilamellar vesi-
les were submitted to five freeze–thaw cycles by freezing
he suspension in liquid nitrogen and thawing it in a 50 ◦C
ater-bath. The dispersions were then sequentially filtered
hrough polycarbonate membranes until an average vesicle
ize of 0.1m was obtained using an extruder device (Lipex
iomembranes Inc., Vancouver, British Columbia, Canada).
n ammonium sulphate gradient was created by replacement
f the extraliposomal medium with a solution containing
50 mM of sodium chloride and 10 mM HEPES (pH 6.9)
sing a desalting column (Econo-Pac® 10 DG; Bio-Rad Lab-
ratories, Hercules, CA). A RFB solution, prepared in the
bove-mentioned buffer, was then incubated with unloaded
iposomes for 1 h under stirring and at a temperature higher
han the phase transition temperature of the respective lipid
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ixture. The non-encapsulated RFB was produced by ultra-
entrifugation at 250 000 × g for 3 h at 15 ◦C in a Beckman
M-80 ultracentrifuge (Beckman Instruments, Inc., Fuller-
on, CA). The pellet was re-suspended in 10 mM HEPES
uffer with 150 mM of sodium chloride (pH 6.9).
.4. Characterisation of RFB liposomal formulations
RFB was quantified spectrophotometrically at 500 nm
fter disruption of the liposomes with ethanol [16]. The lipid
ontent of the samples was determined using a colorimet-
ic technique described by Rouser et al. [33]. Liposomes
ere characterised in terms of lipid composition and by the
ollowing encapsulation parameters: initial and final RFB
o lipid ratios ((RFB/Lip)i and (RFB/Lip)f, respectively);
nd encapsulation efficiency defined as the percentage of
(RFB/Lip)f]/[(RFB/Lip)i]. RFB liposomes mean size was
etermined by dynamic light scattering in a Zetasizer
000HSA (Malvern Instruments, Malvern, UK). As a mea-
ure of particle size distribution of the dispersion, the system
eports the polydispersity index ranging from 0.0 for an
ntirely monodisperse sample up to 1.0 for a polydisperse
uspension. The zeta potential was calculated by dynamic
ight scattering in a Zetasizer 2000 (Malvern Instruments).
.5. Determination of RFB by high-performance liquid
hromatography (HPLC)
.5.1. Chromatographic system
Plasma and tissue levels of RFB were determined by
PLC according to Lau et al. [34] with adaptations.
he HPLC system consisted of a System Gold (Beckman
nstruments, Inc.), a Midas Spark 1.1 autoinjector and a
iode-Array 168 detector (Beckman Instruments, Inc.). The
avelength of this detector was set to 275 nm. The ana-
ytical column was a LiChroCART® (250-4.6), Purospher®
tar RP-8 (5m) (Merck, Darmstadt, Germany). The mobile
hase consisted of 0.05 M potassium dihydrogen phosphate
nd 0.05 M sodium acetate (pH adjusted to 4.0 with acetic
cid)–acetonitrile (53:47, v/v) with a flow rate of 1 mL/min
t 25 ◦C.
.5.2. Preparation of standard solutions
Standard solutions of RFB (100g/mL) were prepared by
eighing the appropriate amount of bulk RFB and dissolv-
ng it in mobile phase. Further stock solutions were made
y diluting the initial stock standard solutions with mobile
hase. Three seven-point calibration curves ranging from
.1g/mL to 2.5g/mL, with a loop of 100L, were used
or the quantification of RFB in plasma and tissues. A stock
olution of 1.0g/mL was stored at −30 ◦C and a sample
f this stock solution was always injected together with the
nalysed samples to verify the precision of the obtained con-
entrations of RFB in samples and controls from their peak
rea concentration response.
i
w
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.6. In vivo fate of RFB formulations
.6.1. Biodistribution studies
A single 20 mg/kg dose of free or liposomal RFB was
njected intravenously into the lateral tail vein of four BALB/c
ice per time point. Mice were sacrificed and blood was
ollected into heparinised tubes and stored at –30 ◦C. The
ung, spleen and liver of mice were removed and stored at
70 ◦C.
.6.2. RFB extraction from blood and tissues
RFB levels in blood and tissues were determined by HPLC
fter an extraction procedure according to Battaglia et al. [35]
nd Benedetti et al. [36] with adaptations. Briefly, 500L
f blood were mixed with 250L of buffer 0.05 M potas-
ium dihydrogen phosphate and 0.05 M sodium acetate (pH
djusted to 4.0 with acetic acid) and extracted twice with 1 mL
f a dichloromethane:isooctane mixture (2:3, v/v) under stir-
ing (15 min), followed by a centrifugation step at 1200 × g
or 10 min in a GPR centrifuge (Beckman Instruments,
nc.).
Liver, lung and spleen tissues were thawed and aliquots of
a. 100 mg were weighed out for each sample and extracted
wice with 2300L of dichloromethane:isooctane mixture by
echanical shaking for 30 min at room temperature, followed
y a centrifugation step at 1200 × g for 10 min in a GPR
entrifuge.
The organic extracts were pooled and evaporated to dry-
ess under nitrogen. The residue was dissolved in 1500L
f mobile phase, filtered and then injected into the HPLC
ystem.
To determine the efficiency of the extraction procedures, a
nown amount of RFB was added to blood and solid tissues
emoved from mice that had not received RFB administration
nd then submitted to the same above-mentioned extraction
rotocol.
.7. Biological evaluation in a M. tuberculosis infection
odel
.7.1. Experimental infection, treatment and bacterial
ounts
BALB/c mice were injected intravenously with 5 × 104
olony-forming units (CFU) of M. tuberculosis H37Rv.
reatment started 3 weeks after infection and consisted of
dministration of 20 mg/kg body weight of RFB in the free
r liposomal form every 3 days over a 2-week period, after
hich CFU counts were performed as described previously
7].
.7.2. Quantitative real-time polymerase chain reaction
PCR) analysisLiver tissue from infected mice was collected and frozen
n TRIzol reagent (Invitrogen, San Diego, CA). Total RNA
as extracted and submitted to reverse transcription using
uperScript® II and Oligo(dT) (Invitrogen) according to
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he manufacturer’s instructions. cDNA was subjected to
eal-time PCR for quantification of hypoxanthine phos-
horibosyltransferase and IFN using the LightCycler®
nstrument (Roche, Indianapolis, IN) as previously described
37].
.7.3. Histology
Representative portions of lung tissue were harvested,
xed in 10% buffered formalin and processed for standard
istological analysis. Sections were stained with haema-
oxylin and eosin for evaluation of pathological changes.
.8. Statistical analysis
The results are given as mean ± standard deviation. Sta-
istical significance was calculated using the Student’s t-test.
alues of P < 0.05 were considered significant.
. Results
.1. RFB liposomes: physicochemical characterisation
The in vivo fate of RFB in the free form or encap-
ulated in liposomes was evaluated in non-infected mice
ollowing i.v. administration. For this purpose, 0.1m mean
ize liposomes were prepared with phospholipids of dif-
erent phase transition temperatures (Tc), with and without
dded PEG (Table 1). The liposomal formulations had
(RFB/Lip)f of 40–62 nmol/mol of lipid, thus allow-
ng comparative in vivo studies at similar liposomal lipid
oses. Two types of liposomes were prepared: conventional
iposomes made with natural or synthetic phospholipids
nd liposomes incorporating the PEG polymer covalently
inked to DSPE (DSPE-PEG), henceforth called PEG
iposomes.
.2. In vivo fate of RFB formulations.2.1. Biodistribution studies
Biodistribution profiles of RFB liposomal formulations
ollowing i.v. administration were assayed. The influence of
p
l
R
f
able 1
hysicochemical properties of rifabutin (RFB) liposomal formulationsa
ipid composition (molar ratio) [Tc] (RFB/Lip)i (nmol/mol) (RFB
C:PG (7:3) [−6 ◦C]/[−6 ◦C] 63 ± 8 62 ±
MPC:DMPG (7:3) [+23 ◦C]/[+23 ◦C] 101 ± 5 55 ±
PPC:DPPG (7:3) [+42 ◦C]/[+42 ◦C] 64 ± 4 46 ±
C:Chol:PEG (1.85:1:0.15) [−6 ◦C]/[]/[] 71 ± 4 60 ±
PPC:PEG (2.85:0.15) [+42 ◦C]/[] 82 ± 3 40 ±
PC:Chol:PEG (1.85:1:0.15) [+58 ◦C]/[]/[] 55 ± 3 36 ±
c: phase transition temperature of phospholipid; (RFB/Lip)i: initial RFB to lipid r
(RFB/Lip)f]/[(RFB/Lip)i] × 100}; Ø: mean diameter of liposomes; PI: polydispers
imyristoyl phosphatidylcholine; DMPG: dimyristoyl phosphatidylglycerol; DPPC:
hol: cholesterol; PEG: poly(ethylene glycol); HPC: hydrogenated phosphatidylch
a Initial lipid concentration, 32mol/mL; (RFB/Lip)i, 50–100 nmol RFB per mntimicrobial Agents 31 (2008) 37–45
iposomal composition on RFB targeting to the spleen, liver
nd lung as well as on RFB blood concentration was evaluated
ver time in comparison with free RFB. The biodistribution
rofiles of various RFB liposomal formulations indicate that
he liver, lung and, particularly, the spleen constitute the main
argeted organs of liposomes (Fig. 1). For the liver (Fig. 1A),
o relevant differences in RFB concentrations were found
t 2 h and 6 h post injection. However, at 24 h post injection
etectable amounts of RFB in the liver were only found in
ice treated with RFB incorporated into liposomes, rang-
ng from 2g/g to a maximum of 4g/g of organ for the
PPC:DPPG formulation. For the spleen (Fig. 1B), a very
igh amount of RFB was found at 2 h post injection in mice
hat received RFB encapsulated in DPPC:DPPG liposomes
81g/g of organ). However, at 6 h post injection the values
ere similar for all RFB formulations, ranging from 5g/g to
g/g of organ. Importantly, as observed in the liver, at 24 h
ost injection detectable RFB values were only achieved for
iposomal formulations. Higher values were found in mice
reated with liposomal formulations prepared with phospho-
ipids of high Tc (DPPC:DPPG, HPC:Chol:DSPE-PEG and
PPC:PEG). For the lung (Fig. 1C), the RFB formulation
repared with DPPC:DPPG showed the highest amount of
on-metabolised RFB at 2 h post injection (27g/g of organ).
t 24 h post injection, RFB was only detected in the lung
f mice treated with lipid mixtures of higher Tc, namely
PPC:DPPG, HPC:Chol:DSPE-PEG and DPPC:PEG, with
ung concentrations ranging from 2g/g to 4g/g of organ.
inally, the concentration of RFB in total blood 2 h post
njection was higher in mice treated with phospholipids of
igher Tc, namely DPPC:DPPG and HPC:Chol:DSPE-PEG
iposomes, compared with free RFB or the other RFB formu-
ations (Fig. 1D). The higher blood residence time of RFB
hen encapsulated into liposomes made with phospholipids
f long and saturated lipid mixtures is in accordance with the
iterature [38,39].
Overall, our results show more efficient delivery to the
iver, spleen and lung, of RFB encapsulated in liposomes
repared with phospholipids of high Tc. In addition, the
ipid composition DPPC:DPPG most effectively delivered
FB to these organs. This formulation was therefore selected
or biological evaluation in a model of disseminated TB
/Lip)f (nmol/mol) EE (%) Ø (m) (PI) Zeta potential (mV)
8 102 ± 10 0.10 (<0.2) −33 ± 2
3 55 ± 6 0.10 (<0.2) −31 ± 3
6 72 ± 5 0.10 (<0.2) −33 ± 1
8 90 ± 10 0.13 (<0.2) −4 ± 1
1 49 ± 5 0.14 (<0.2) −5 ± 1
2 64 ± 3 0.12 (<0.2) −3 ± 2
atio; (RFB/Lip)f: final RFB to lipid ratio; EE: encapsulation efficiency {=
ity index; PC: egg phosphatidylcholine; PG: phosphatidylglycerol; DMPC:
dipalmitoyl phosphatidylcholine; DPPG: dipalmitoyl phosphatidylglycerol;
oline; []: not applicable.
ol of lipid.
M.M. Gaspar et al. / International Journal of Antimicrobial Agents 31 (2008) 37–45 41
Fig. 1. Pharmacokinetics and biodistribution of rifabutin (RFB) formulations as measured by non-metabolised RFB in BALB/c mice in (A) liver (g/g liver);
(B) spleen (g/g spleen); (C) lung (g/g lung); and (D) total blood (g/total blood) following intravenous administration of the following formulations (dose
20 mg/kg RFB): free RFB (black bar); PC:PG (bar with diagonal lines); DMPC:DMPG (grey bar); DPPC:DPPG (bar with horizontal lines); PC:Chol:DSPE-PEG
( G (bar w
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ean ± standard deviation (n = 4 mice per selected time and per RFB formula
hosphatidylcholine; DMPG, dimyristoyl phosphatidylglycerol; DPPC, d
holesterol; PEG, poly(ethylene glycol); DSPE-PEG, PEG covalently linked
n which the liver, spleen and lung are the major target
rgans.
.3. Biological evaluation of RFB formulations in a
odel of M. tuberculosis disseminated infection
.3.1. Bacterial burdens after treatment with free or
iposomal RFB
To assess the antimycobacterial activity of encapsulated
ersus free RFB in vivo, mice were infected intravenously
ith 4.7 log10 CFU of M. tuberculosis. Before treatment
as started at 3 weeks post infection, bacillary burdens had
ncreased in all organs (data not shown). After a 2-week treat-
ent period, a significant reduction in the bacterial loads
f all primary target organs was observed for treated mice
ompared with untreated mice (Fig. 2). No significant dif-
erences in bacterial counts were found between the lungs
f mice treated with free or liposomal RFB (Fig. 2). How-
ver, administration of RFB encapsulated in DPPC:DPPG
iposomes resulted in a significant reduction in the number
f bacilli recovered both from the spleen and liver compared
ith administration of free RFB (Fig. 2).
i
w
d
iith grid). Liposomes mean size was 0.1m. The results are expressed as
C, egg phosphatidylcholine; PG, phosphatidylglycerol; DMPC, dimyristoyl
yl phosphatidylcholine; DPPG, dipalmitoyl phosphatidylglycerol; Chol,
aroyl-phosphatidylethanolamine; HPC, hydrogenated phosphatidylcholine.
.3.2. IFNγ expression in the liver after treatment with
ree or liposomal RFB
Production of IFN by T-cells, induced upon M. tubercu-
osis infection, plays a protective role through macrophage
ctivation [6]. Therefore, we assessed relative IFN mRNA
xpression in the liver by real-time PCR to determine whether
he reduction in bacterial burdens found in the organs of RFB-
reated mice was associated with an altered IFN profile.
ompared with untreated mice, expression of IFN was not
ifferent in mice treated with free RFB but was significantly
ecreased in the livers of mice treated with liposomal RFB
Fig. 3). This result is in accordance with the reduced num-
er of bacteria present in the liver of these mice and with the
ssociated reduced level of microbial inflammatory stimulus.
.3.3. Histological analysis of lungs after treatment with
ree or liposomal RFB
As noted above, no significant differences were observed
n the number of bacilli found in the lungs of mice treated
ith encapsulated RFB compared with treatment with free
rug. However, the outcome of the disease in M. tuberculosis-
nfected lung depends not only on the bacterial burden but
42 M.M. Gaspar et al. / International Journal of Antimicrobial Agents 31 (2008) 37–45
Fig. 2. Bacterial burdens following treatment with liposomal or free rifabutin (RFB). BALB/c mice were infected intravenously with 4.7 log10 colony-forming
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(nits (CFU) of Mycobacterium tuberculosis. At 3 weeks after infection, th
ith liposomal RFB (L-RFB) over a 2-week period. The therapeutic effects
nd of treatment (5 weeks after infection). The results are expressed as mean
f three independent experiments. Statistical significance was determined b
lso on the characteristics of the inflammatory response,
hich can be associated with tissue damage [40]. We
herefore analysed lung tissue sections to determine the
ffect of treatment with RFB on histopathology. The lung
f untreated mice showed an intense acute inflammatory
esponse (Fig. 4A) containing numerous neutrophils, cor-
elating with the high CFU counts. In mice treated with
ig. 3. Expression of interferon-gamma (IFN) in livers of infected mice.
ALB/c mice were infected intravenously with 4.7 log10 colony-forming
nits of Mycobacterium tuberculosis. At 3 weeks after infection, the exper-
mental groups were either left untreated (UT) or treated with free rifabutin
RFB) or with liposomal RFB (L-RFB). The relative expression of IFN
RNA was assessed by real-time polymerase chain reaction in the liver at
he end of treatment. The results are expressed as mean ± standard devia-
ion (n = 5). Statistical significance was determined using Student’s t-test:
P < 0.05.
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imental groups were either left untreated (UT) or treated with free RFB or
reatments were evaluated in the primary target organs by CFU counts at the
dard deviation (n = 5 mice). Results are from one experiment representative
nt’s t-test: *P < 0.05; **P < 0.01; ***P < 0.005.
ree RFB, the cellular infiltrate was milder, consisting of
ymphocytes, macrophages and epithelioid cells, with numer-
us granulomata scattered throughout the lung parenchyma
Fig. 4B). In the lung of mice treated with liposomal RFB,
he inflammatory infiltrate also had a mononuclear pro-
le. Importantly, this inflammatory response was diminished
ompared with that of mice treated with free RFB and was
ssociated with a decreased number of granulomata that were
estricted to the perivascular area (Fig. 4C). Therefore, even
hough no significant differences were found in the bacterial
oads in the lung of mice treated with either free or liposomal
FB, histopathology shows that treatment with encapsulated
FB is associated with lower levels of lung inflammation.
. Discussion
The rationale for the association of RFB with liposomes,
s tested here, is to achieve an increased therapeutic effect
f this second-line antimycobacterial drug through its pref-
rential accumulation in infected macrophages present in the
ain target organs of M. tuberculosis whilst reducing its tox-
city [41,42] and the periodicity of the treatment regimen,
hich may contribute to compliance in long-term treatment
egimens. Taking this into consideration, different liposo-
al formulations were developed and their in vivo fate was
valuated by quantifying the non-metabolised RFB follow-
ng systemic administration. The biodistribution profiles of
FB liposomal formulations indicate that the liver and spleen
onstitute the main targeted organs of liposomes. In fact, 24 h
ost injection it was only possible to detect non-metabolised
FB in both organs in mice receiving RFB in the liposo-
al form. The quantity of non-metabolised RFB detected
n the lung was lower than the amounts observed in the
M.M. Gaspar et al. / International Journal of A
Fig. 4. Lung histopathology in infected mice. BALB/c mice were infected
intravenously with 4.7 log10 colony-forming units of Mycobacterium tuber-
culosis. At 3 weeks after infection, the experimental groups were either left
untreated (A) or treated with free rifabutin (RFB) (B) or with encapsulated
RFB (C). The lungs of mice from the different experimental groups were
harvested after the end of treatment and serial tissue sections were stained
with haematoxylin and eosin (magnification 40×). (A) An intense acute
inflammatory cellular response in the lung of untreated mice. (B, C) The
cellular infiltrates were milder, consisting mostly of mononuclear cells. The
granuloma distribution between the two treatments differed. In (B), gran-
ulomata were predominantly found scattered throughout the parenchyma
(arrowheads), whilst in (C) granulomata were restricted to the perivascular
area (arrows).
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iver and spleen and these levels were lipid composition-
ependent. The observation that RFB liposomal formulations
repared with phospholipids of higher Tc resulted in the
ighest amounts of non-metabolised RFB in the lung is
n accordance with the higher stability of these liposomes.
s extensively described in the literature, the higher sta-
ility of liposomes results in lower drug release as well as
lteration of the biodistribution profile of the drug within
iposomes [21,43]. In the present work, it was only possible
o detect non-metabolised RFB 24 h post injection for RFB
iposomes prepared with rigid phospholipids. In the future,
fforts should be pursued to develop other liposomal formu-
ations to optimise the targeting of antimycobacterial agents
o the lung.
Based on the biodistribution studies, the rigid phospho-
ipids DPPC and DPPG were selected for encapsulating RFB
o evaluate comparatively the therapeutic effect with free RFB
n a disseminated M. tuberculosis model of infection. Admin-
stration of free or liposomal RFB to mice infected with M.
uberculosis resulted in a significant decrease in the bacterial
oads in all the target organs analysed. Additionally, a statisti-
ally significant higher antimycobacterial effect of liposomal
FB was achieved in comparison with free RFB in liver and
pleen.
Encapsulation of RFB in liposomes, in addition to improv-
ng the efficacy of the antibiotic, also decreases the potentially
amaging inflammatory responses in infected organs, namely
n the lung, where no statistically significant differences in
ycobacterial loads were found between mice treated with
ree or liposomal RFB.
In our model of disseminated infection, increased reduc-
ion of bacterial burdens in mice treated with liposomal RFB
as achieved in the liver and spleen but not in the lung, which
s the main target organ of M. tuberculosis in immunocom-
etent hosts. For the treatment of pulmonary TB, it would be
f interest to test administration by the aerogenic route of
iposome-encapsulated antimycobacterial drugs. However,
IV-induced immunosuppression modifies the clinical pre-
entation of TB, resulting in an increased occurrence of
xtrapulmonary M. tuberculosis infections, including dis-
eminated forms of the disease [44]. Our results showing
hat RFB encapsulated in liposomes has a superior therapeu-
ic effect in the spleen and liver suggest that encapsulated
FB could be a potential approach for more effective control
f extrapulmonary TB in HIV/acquired immune deficiency
yndrome (AIDS) patients. There is a need for better treat-
ent regimens for the increasing number of cases of HIV/M.
uberculosis co-infection. The combination of highly active
ntiretroviral therapy (HAART) with the standard first-line
B drug rifampicin has been described to lead to subtherapeu-
ic concentrations of antiretroviral drugs through activation of
he hepatic cytochrome P450 system [44,45]. Alternatively
o rifampicin, RFB can be used, with an appropriate dose
eduction, in combination with HAART [44,45], which could
e achieved through encapsulation in liposomes. Finally, the
mergence of MDR tuberculosis in HIV/AIDS patients is
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ne of the major concerns among public health entities [46]
nd also justifies the therapeutic use of encapsulated RFB
n patients infected with M. tuberculosis strains resistant to
ifampicin but not to RFB [28,46].
In conclusion, DPPC:DPPG RFB liposomes were the most
ffective tested formulation to deliver RFB to the liver, spleen
nd lung. The superior therapeutic effect of this RFB lipo-
omal formulation in the mouse model of disseminated TB
ompared with non-incorporated antibiotic makes such a
herapeutic approach a good candidate for the treatment of
B in patients co-infected with HIV.
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